[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT72004A - Process for preparing antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine - Google Patents

Process for preparing antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine

Info

Publication number
PT72004A
PT72004A PT72004A PT7200480A PT72004A PT 72004 A PT72004 A PT 72004A PT 72004 A PT72004 A PT 72004A PT 7200480 A PT7200480 A PT 7200480A PT 72004 A PT72004 A PT 72004A
Authority
PT
Portugal
Prior art keywords
tetrahydro
cis
naphthalenamine
phenyl
derivatives
Prior art date
Application number
PT72004A
Other languages
Portuguese (pt)
Other versions
PT72004B (en
Inventor
Willard Mckowan Welch
Charles Armon Harbert
Billie Kenneth Koe
Allen Richard Kraska
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22221931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT72004(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of PT72004A publication Critical patent/PT72004A/en
Publication of PT72004B publication Critical patent/PT72004B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
    • C07C209/14—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups
    • C07C209/16—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups with formation of amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/21—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/28—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of CHx-moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Novel cis-isomeric derivatives of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine are useful as antidepressant agents. These novel compounds act to block the synaptosomal uptake of serotonin (5-hydroxy-tryptamine), thereby alleviating serotonin abnormalities at central receptor sites. The preferred embodiment is the enantiomer cis-(1S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthal enamine and its pharmaceutically acceptable acid addition salts.
PT72004A 1979-11-01 1980-10-31 Process for preparing antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine PT72004B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/090,240 US4536518A (en) 1979-11-01 1979-11-01 Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine

Publications (2)

Publication Number Publication Date
PT72004A true PT72004A (en) 1980-11-01
PT72004B PT72004B (en) 1981-08-31

Family

ID=22221931

Family Applications (1)

Application Number Title Priority Date Filing Date
PT72004A PT72004B (en) 1979-11-01 1980-10-31 Process for preparing antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine

Country Status (38)

Country Link
US (1) US4536518A (en)
EP (1) EP0030081B1 (en)
JP (1) JPS605584B2 (en)
KR (2) KR840002001B1 (en)
AT (1) ATE2668T1 (en)
AU (1) AU517357B2 (en)
BA (2) BA97150B1 (en)
BG (1) BG60333B2 (en)
CA (1) CA1130815A (en)
CS (4) CS238609B2 (en)
DD (2) DD155615A5 (en)
DE (2) DE19775012I2 (en)
DK (1) DK153390C (en)
EG (1) EG15527A (en)
ES (2) ES8201949A1 (en)
FI (1) FI68806C (en)
GR (1) GR70781B (en)
HK (1) HK82284A (en)
HR (2) HRP930199B1 (en)
HU (1) HU182224B (en)
IE (1) IE50395B1 (en)
IL (1) IL61374A (en)
IN (2) IN159643B (en)
LU (1) LU88330I2 (en)
LV (2) LV5457A3 (en)
MX (1) MX5980E (en)
MY (1) MY8500326A (en)
NL (1) NL940018I1 (en)
NO (2) NO148996C (en)
NZ (1) NZ195407A (en)
PH (1) PH17319A (en)
PT (1) PT72004B (en)
SG (1) SG56584G (en)
SI (2) SI8012798A8 (en)
SU (2) SU1014467A3 (en)
UA (2) UA6311A1 (en)
YU (2) YU41951B (en)
ZA (1) ZA806726B (en)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004002L (en) * 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik THERAPEUTICALLY APPLICABLE TETRALIN DERIVATIVES
US4839104A (en) * 1987-06-11 1989-06-13 Pfizer, Inc. Process for preparing sertraline intermediates
US4777288A (en) * 1987-06-11 1988-10-11 Pfizer Inc. Process for preparing a 4,4-diphenylbutanoic acid derivative
FR2623802B1 (en) * 1987-11-26 1990-05-04 Lucien Laboratoires DERIVATIVES OF AMINO-4 TRIFLUOROMETHYL-1 TETRALINES. THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
US4855500A (en) * 1988-05-04 1989-08-08 Pfizer Inc. Process for preparing a ketimine
FR2632633B1 (en) * 1988-06-08 1991-04-05 Delalande Sa PROCESS FOR THE PREPARATION OF 4-ARYL-1-TETRALONES
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4940731A (en) * 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
DE69004529T2 (en) * 1989-08-30 1994-02-24 Pfizer Use of sertraline to treat chemical addiction.
US5130338A (en) * 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
FR2665443B1 (en) * 1990-08-03 1992-11-06 Lucien Laboratoires DERIVATIVES OF AMINO-4-METHYL-1-TETRALINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
US5082970A (en) * 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114948D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
GB9114947D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5196607A (en) * 1992-02-14 1993-03-23 Pfizer Inc. Process for preparing ketone enantiomer
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5288916A (en) * 1993-03-25 1994-02-22 Bend Research, Inc. Enantiomeric resolution of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone
JP2686366B2 (en) * 1993-11-30 1997-12-08 ファイザー・インコーポレーテッド Method for producing chiral tetralone
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US6410794B1 (en) 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US6455736B1 (en) 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
AU5966196A (en) * 1995-06-08 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
AU6776196A (en) * 1995-08-16 1997-03-12 Eli Lilly And Company Potentiation of serotonin response
US5734083A (en) * 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
HU222341B1 (en) * 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Process for producing sertraline and intermediate used in this process
TW526195B (en) * 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
AU739261B2 (en) * 1997-07-01 2001-10-11 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
EP0928784B1 (en) * 1997-12-11 2002-06-12 TORCAN CHEMICAL Ltd Sertraline polymorph having improved water solubility
IN191358B (en) 1998-01-16 2003-11-29 Pfizer Prod Inc
WO1999046233A1 (en) * 1998-03-09 1999-09-16 Sumika Fine Chemicals Co., Ltd. Benzyl alcohol derivatives
ES2217748T3 (en) 1998-03-18 2004-11-01 Ciba Specialty Chemicals Holding Inc. PROCEDURE FOR CIS-SELECTIVE CATALYTIC HYDROGENACIN OF CYCLOHEXYLIDENAMINS.
FR2777000B1 (en) * 1998-04-01 2002-09-27 Catalys PROCESS FOR THE PREPARATION OF RACEMIC SERTRALINE
EP0957099B1 (en) * 1998-04-15 2002-11-20 Pfizer Products Inc. Heterocyclic carboxamides
US6054614A (en) * 1998-04-23 2000-04-25 Ciba Specialty Chemicals Corporation Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds
HU226423B1 (en) * 1998-05-05 2008-12-29 Egis Gyogyszergyar Nyrt Process for producing a 1(2h)-naphtalene-1-ylidene derivative
HU226424B1 (en) * 1998-05-05 2008-12-29 Egis Gyogyszergyar Nyrt Process for producing enantiomer mixture for preparation of sertraline
IN182588B (en) 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
DE19830201A1 (en) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Antidepressant
WO2000021521A2 (en) * 1998-10-13 2000-04-20 Pfizer Products Inc. Sertraline oral concentrate
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
IL132500A0 (en) 1998-10-29 2001-03-19 Pfizer Prod Inc Stereoselective microbial reduction of a racemic tetralone
WO2000025598A1 (en) * 1998-11-03 2000-05-11 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
AU1633600A (en) * 1998-11-27 2000-06-19 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
EP1630156A1 (en) * 1998-11-27 2006-03-01 Teva Pharmaceutical Industries Ltd Sertraline hydrochloride polymorphs
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
WO2000051972A1 (en) * 1999-03-01 2000-09-08 Pfizer Limited 1,2,3,4-tetrahydro-1-naphthalenamine compounds useful in therapy
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
US6593496B1 (en) 1999-06-09 2003-07-15 Pfizer Inc Process for preparing sertraline from chiral tetralone
AU6275900A (en) * 1999-07-29 2001-02-19 Ciba Specialty Chemicals Holding Inc. Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
US6495721B1 (en) * 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
IN185109B (en) * 1999-09-01 2000-11-18 Torrent Pharmaceuticals Ltd
DK174219B1 (en) * 1999-10-27 2002-09-30 Gea Farmaceutisk Fabrik As Improved synthesis of racemic sertraline
US7442838B2 (en) * 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
US20050119351A1 (en) * 1999-10-29 2005-06-02 Van Der Schaaf Paul A. Polymorphic forms of sertraline hydrochloride
TWI260315B (en) 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride
WO2001036377A1 (en) * 1999-11-16 2001-05-25 Ciba Specialty Chemicals Holding Inc. Process for the preparation of ketimines
AU1998701A (en) * 1999-11-16 2001-05-30 Ciba Specialty Chemicals Holding Inc. Process for the preparation of ketimines
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
PT1248605E (en) 1999-12-21 2007-03-30 Teva Pharma Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
CA2395231C (en) 1999-12-23 2006-08-15 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
IN187170B (en) 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
CA2402656A1 (en) * 2000-03-14 2001-09-20 Teva Pharmaceutical Industries Ltd. Process for preparing(+)-cis-sertraline
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
IN192343B (en) * 2000-05-26 2004-04-10 Ranbaxy Lab Ltd
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
DE60119047D1 (en) * 2000-08-31 2006-06-01 Pfizer Phenoxyphenyl heterocycles as serotonin reuptake inhibitors
US6482440B2 (en) 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
EP1397343A1 (en) * 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
US6723878B2 (en) 2001-06-15 2004-04-20 Orion Corporation Fermion Method for preparing sertraline
WO2002102761A1 (en) * 2001-06-15 2002-12-27 Orion Corporation Fermion A novel process for the preparation of (is-cis) -4-(3, 4-dichlorophenyl) -1, 2, 3, 4 - tetrahydro-n-methyl-1-naphthalenamine
CN103288815A (en) * 2001-10-12 2013-09-11 阿泽范药品公司 Beta-lactamyl vasopression V1a antagonists
KR20040088519A (en) 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. Active Agent Delivery Systems and Methods for Protecting and Administering Active Agents
US6897340B2 (en) * 2002-04-29 2005-05-24 Teva Pharmaceutical Industries Ltd. Processes for preparation of polymorphic form II of sertraline hydrochloride
AU2003254475A1 (en) * 2002-07-29 2004-02-16 Cipla Limited Sertraline
AU2003274608A1 (en) * 2002-11-07 2004-06-07 Sunil Sadanand Nadkarni Process for preparation of polymorphic form of sertraline hydrochloride
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc Method and composition for treating neurodegenerative disorders
WO2004087732A2 (en) * 2003-03-11 2004-10-14 Sun Pharmaceutical Industries Limited Process for the preparation of (1s, 4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphthylamine
MXPA05011038A (en) * 2003-04-14 2006-01-24 Teva Pharma Hydrogenation of imine intermediates of sertraline with catalysts.
WO2005000786A1 (en) * 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Sertraline compositions
US20050070577A1 (en) * 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US7173153B2 (en) * 2003-07-15 2007-02-06 Recordati Industria Chimica E. Farmaceutica S.P.A. Sertraline hydrochloride form II and methods for the preparation thereof
WO2005012225A1 (en) * 2003-07-15 2005-02-10 Recordati Industria Chimica E Farmaceutica S.P.A. Methods for preparing sertraline hydrochloride polymorphs
HU227495B1 (en) * 2003-07-21 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing of imine intermediate
US7262327B2 (en) * 2003-09-05 2007-08-28 Teva Pharmaceutical Industries Ltd. Recycling process for preparing sertraline
RU2320369C2 (en) 2003-09-12 2008-03-27 Пфайзер Инк. Combinations containing alpha-2-delta ligands and serotonin/noradrenaline reuptake inhibitors
CN1878546A (en) * 2003-09-12 2006-12-13 沃纳-兰伯特公司 Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders
US7402680B2 (en) * 2003-09-17 2008-07-22 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
US7893300B2 (en) * 2003-11-04 2011-02-22 Cipla Limited Process for the preparation of polymorphs of selective serotonin reuptake inhibitor
US20050250803A1 (en) * 2003-11-26 2005-11-10 Pfizer Inc Combination of dopamine agonists and monoamine reuptake inhibitors
DK1689721T3 (en) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazole derivatives as GSK-3 inhibitors
PL1691811T3 (en) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
CA2567249A1 (en) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Lithium combinations, and uses related thereto
BRPI0509592A (en) * 2004-05-06 2007-09-25 Cydex Inc flavored formulations containing sulfoalkyl ether sertraline and cyclodextrin
AR049401A1 (en) 2004-06-18 2006-07-26 Novartis Ag AZA-BICICLONONANS
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US7345201B2 (en) * 2005-02-23 2008-03-18 Teva Pharmaceutical Industries, Ltd. Processes for preparing sertraline
AU2006227199A1 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
JP2006265169A (en) * 2005-03-24 2006-10-05 Tokuyama Corp Method for producing alkylidene succinic acid compound
GB0507090D0 (en) * 2005-04-07 2005-05-11 Sandoz Ag Process for preparing polymorphic form ll of sertraline hydrochloride
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
EP1871356A1 (en) * 2005-04-22 2008-01-02 Wyeth a Corporation of the State of Delaware Dihydrobenzofuran derivatives and uses thereof
WO2006116150A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
MX2007013021A (en) 2005-04-22 2008-01-11 Wyeth Corp Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists.
BRPI0610027A2 (en) * 2005-04-22 2010-05-18 Wyeth Corp chroman and chromene derivatives and their uses
GT200600158A (en) * 2005-04-22 2006-11-28 CRYSTALS FORMED OF {[(2R) -7- (2,6-DICLOROPHENYL) -5-FLUORO-2,3-DIHIDRO-1-BENZOFURAN-2-IL] METHYL} AMINA
CA2576097C (en) * 2005-06-03 2009-10-27 Hetero Drugs Limited A highly stereoselective synthesis of sertraline
US20070100165A1 (en) * 2005-06-09 2007-05-03 Ronen Borochovitz Process for preparation of sertraline hydrochloride form I
ZA200711123B (en) * 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
EP1904843A2 (en) 2005-07-08 2008-04-02 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
RU2466991C2 (en) 2005-07-19 2012-11-20 Эйзеван Фармасьютиклз, Инк. β-LACTAMYL-SUBSTITUTED ANALOGUES OF PHENYLALANINE, CYSTEINE AND SERINE AS VASOPRESSIN ANTAGONISTS
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (en) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド GABA receptor-mediated regulation of neurogenesis
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
ES2566479T3 (en) * 2006-01-06 2016-04-13 Sunovion Pharmaceuticals Inc. Monoamine reabsorption inhibitors based on tetralone
EP1858838A1 (en) * 2006-01-23 2007-11-28 Teva Pharmaceutical Industries Ltd. A recycling process for preparing sertraline
FR2912057B1 (en) * 2007-02-07 2009-04-17 Sanofi Aventis Sa PHARMACEUTICAL COMPOSITION COMPRISING SAREDUTANT AND A SELECTIVE SEROTONIN RECAPTURE INHIBITOR OR SEROTONIN / NOREPINEPHRINE RECAPTURE INHIBITOR
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
KR20080105104A (en) * 2006-03-24 2008-12-03 와이어쓰 Novel therapeutic combinations for the treatment of depression
WO2007119247A2 (en) * 2006-04-17 2007-10-25 Unichem Laboratories Limited Improved manufacturing procedure for the preparation of polymorphic form ii of cis-(1s)-n-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthleneamine hydrochloride (sertraline hydrochloride)
TR200808115T1 (en) * 2006-04-28 2009-03-23 Sandoz Ag Process for the Preparation of 4 (S, R) - (3,4-dichlorophenyl) -3,4-dihydro-1 (2H) -naphthalen-1-ylidene] methylamine
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7518019B2 (en) 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
WO2007146796A2 (en) * 2006-06-13 2007-12-21 Ramot At Tel-Aviv University Ltd. Antiproliferative compounds, compositions and methods of use
US7893053B2 (en) * 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20060257475A1 (en) * 2006-08-17 2006-11-16 Boehringer Ingelheim International Gmbh Stable Sertraline Hydrochloride Formulation and Method
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008034032A2 (en) * 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
FR2909376A1 (en) * 2006-11-30 2008-06-06 Cerep Sa PROCESSES FOR PREPARING DESMETHULSERTRALINE OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
US20090062399A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sertraline
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9260413B2 (en) * 2010-03-04 2016-02-16 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
WO2011163231A2 (en) 2010-06-21 2011-12-29 Theracos, Inc. Combination therapy for the treatment of diabetes
ES2662350T3 (en) 2010-07-01 2018-04-06 Azevan Pharmaceuticals, Inc. Procedures for the treatment of posttraumatic stress disorder
WO2012123922A1 (en) 2011-03-17 2012-09-20 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
KR101340270B1 (en) * 2011-11-10 2013-12-10 보령제약 주식회사 selective preparation method of (+)-cis-sertraline
SG11201500729SA (en) * 2012-10-18 2015-06-29 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
JP7255967B2 (en) 2014-03-28 2023-04-11 アゼヴァン ファーマスーティカルズ，インコーポレイテッド Compositions and methods for treating neurodegenerative diseases
WO2015193921A1 (en) 2014-06-20 2015-12-23 Council Of Scientific And Industrial Research An organocatalytic asymmetric synthesis of antidepressants
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
JP6695323B2 (en) * 2014-08-11 2020-05-20 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ Pyrido [3,4-d] pyrimidine-2,4 (1H, 3H) -dione derivative
EP3180345B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
JP6667092B2 (en) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ Pyrrolo [3,2-d] pyrimidine-2,4 (3H, 5H) -dione derivative
EP4166237A1 (en) 2015-09-21 2023-04-19 S.C. Johnson & Son, Inc. System for mixing and dispensing
TW201919625A (en) 2017-09-15 2019-06-01 美商愛治凡製藥公司 Compositions and methods for treating brain injury
WO2020043716A1 (en) 2018-08-27 2020-03-05 Katholieke Universiteit Leuven Pharmacological targeting of de novo serine/glycine synthesis
GB2630572A (en) 2023-05-29 2024-12-04 Novumgen Ltd An orally disintegrating tablet of sertraline and its process of preparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887509A (en) * 1956-11-05 1959-05-19 Lilly Co Eli Hydroxybenzoyl benzoate salt of beta-(o-chlorophenyl)-beta-hydroxyethyl isopropylamine
US3704323A (en) * 1969-12-23 1972-11-28 Squibb & Sons Inc Indane derivatives
US4029731A (en) * 1974-11-06 1977-06-14 Pfizer Inc. Aminophenyltetralin compounds
US4045488A (en) * 1974-11-06 1977-08-30 Pfizer Inc. Aminophenyltetralin compounds

Also Published As

Publication number Publication date
FI68806B (en) 1985-07-31
LV5457A3 (en) 1994-03-10
CS238618B2 (en) 1985-12-16
IE50395B1 (en) 1986-04-16
NZ195407A (en) 1984-05-31
DE19775012I2 (en) 2001-02-08
HRP930199B1 (en) 1996-02-29
BG60333B2 (en) 1994-11-30
EP0030081A1 (en) 1981-06-10
NO148996B (en) 1983-10-17
SI8310672A8 (en) 1996-04-30
FI68806C (en) 1985-11-11
IN159644B (en) 1987-05-30
LU88330I2 (en) 1994-05-04
SU1014467A3 (en) 1983-04-23
UA6311A1 (en) 1994-12-29
IL61374A0 (en) 1980-12-31
KR830004202A (en) 1983-07-06
MY8500326A (en) 1985-12-31
DD203045A5 (en) 1983-10-12
GR70781B (en) 1983-03-23
IE802259L (en) 1981-05-01
IL61374A (en) 1983-10-31
DK153390C (en) 1988-12-05
IN159643B (en) 1987-05-30
KR840002001B1 (en) 1984-10-27
CA1130815A (en) 1982-08-31
EG15527A (en) 1987-04-30
ES496443A0 (en) 1982-01-16
FI803398L (en) 1981-05-02
YU67283A (en) 1983-10-31
SG56584G (en) 1985-03-08
DD155615A5 (en) 1982-06-23
YU41951B (en) 1988-02-29
HU182224B (en) 1983-12-28
NL940018I1 (en) 1994-10-17
LV5456A3 (en) 1994-03-10
ATE2668T1 (en) 1986-03-15
KR840002000B1 (en) 1984-10-27
ES8201949A1 (en) 1982-01-16
YU279880A (en) 1983-09-30
HK82284A (en) 1984-11-09
SI8012798A8 (en) 1994-12-31
ES506892A0 (en) 1982-09-01
ES8207123A1 (en) 1982-09-01
NO803258L (en) 1981-05-04
NO148996C (en) 1984-01-25
NO1996011I1 (en) 1996-09-24
BA97150B1 (en) 1998-12-28
PT72004B (en) 1981-08-31
DK395280A (en) 1981-05-02
BA97149B1 (en) 1998-12-28
YU42846B (en) 1988-12-31
SU1034602A3 (en) 1983-08-07
ZA806726B (en) 1981-10-28
MX5980E (en) 1984-09-12
JPS5686137A (en) 1981-07-13
AU6389780A (en) 1981-05-07
DK153390B (en) 1988-07-11
EP0030081B1 (en) 1983-03-02
CS354291A3 (en) 1992-12-16
JPS605584B2 (en) 1985-02-12
CS238617B2 (en) 1985-12-16
UA6301A1 (en) 1994-12-29
HRP931527B1 (en) 1996-04-30
US4536518A (en) 1985-08-20
AU517357B2 (en) 1981-07-23
DE3062225D1 (en) 1983-04-07
CS238609B2 (en) 1985-12-16
PH17319A (en) 1984-07-20

Similar Documents

Publication Publication Date Title
EG15527A (en) Process for preparing derivatives of cis-4-phenyl-1,2,3,4,tetrahydro-1-naphthalenamine
IE802260L (en) Tetrahydronaphthalene amines.
HUP9603493A2 (en) Process for producing sertraline and intermedier used in this process
WO1999055686A3 (en) Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds
JPS57206638A (en) Preparation of tetralin derivative
JPS57212125A (en) Tetrahydronaphthalene derivative and its preparation